Because the fibroblast growth factor receptor 3 variant is widely expressed throughout the body, achondroplasia has multisystemic effects that affect muscle, cardiorespiratory health, neurological function, and health-related quality of life. To assess benefits beyond growth that may have significant implications for complications and health-related quality of life in children with achondroplasia, this study examined the effectiveness, safety, and tolerability of once-weekly navepegritide, an investigational prodrug of C-type natriuretic peptide.
10 hospitals in Australia, Denmark, Canada, Ireland, Spain, New Zealand, and the US were enrolled in this trial from March to August 2023. The participants between the ages of 2 and 11 who met the eligibility requirements had their height measured at least 6 months before randomization, had achondroplasia verified by genetic testing, and were not receiving treatment with growth-promoting drugs.
Age and sex were used to stratify the enrolled subjects. All 84 individuals were examined for safety and effectiveness results, including 2 who stopped therapy; those with radiographic evidence of closed growth plates, scheduled bone surgery, severe untreated sleep apnea, or other illnesses known to impair growth were eliminated.
A 2:1 randomization was used to assign 84 kids to either navepegritide (n = 57) or a placebo (n = 27). Despite the early discontinuation of two navepegritide patients, all subjects were included in analyses. When compared to a placebo, navepegritide substantially increased annualized growth velocity at week 52 (difference 1.49 cm/year; 95% CI, 1.05–1.93; P<.001).
The tibial-femoral angle, mechanical axis deviation, fibula-tibia length ratio, and physical functioning ratings in children under 5 showed further advantages. There were no fatalities or significant side effects associated with the therapy. There were few injection site responses and no reports of fractures or clinical hypotension.
Overall, navepegritide medication produced a statistically significant increase in annualized growth velocity in children with achondroplasia in this randomized clinical study, although the safety and tolerability profile was comparable to that of a placebo.
Reference:
Savarirayan, R., McDonnell, C., Bacino, C. A., Hoernschemeyer, D. G., Legare, J. M., Abuzzahab, M. J., Hofman, P. L., Campeau, P. M., de Bergua Domingo, J. M., Ward, L. M., Smit, K., Smith, A., Mao, M., Ominsky, M. S., Freiberg, L. C., Shu, A. D., & Hove, H. B. (2025). Once-weekly navepegritide in children with achondroplasia: The APPROACH randomized clinical trial: The APPROACH randomized clinical trial. JAMA Pediatrics. https://doi.org/10.1001/jamapediatrics.2025.4771
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.